













doi:10.101Lung Function and Long-Term Complications after
Allogeneic Hematopoietic Cell Transplant
Eric C. Walter,1,2 Mauricio Orozco-Levi,2,3 Alba Ramirez-Sarmiento,2,3 Afonso Vigorito,2
Paulo V. Campregher,2 Paul J. Martin,2 Mary E. Flowers,2 Jason W. Chien1,2It is unknown if diminished pulmonary function early after allogeneic hematopoietic transplant is associated
with poor long-term outcomes. The objective of this study was to determine if posttransplant lung function is
associated with 5-year nonrelapse mortality (NRM) and the development of chronic graft-versus-host dis-
ease (cGVHD). Retrospective analysis was done for 2158 patients who had routine pulmonary function test-
ing 60-120 days after transplant between 1992 and 2004. Cox regression was used to assess the hazard ratio
for 5-year NRM. A second analysis assessed the hazard ratio for the development of cGVHD. Lung function
score was the primary exposure, and was calculated according to forced expiratory volume in 1 second
(FEV1) and carbon monoxide diffusion capapcity (DLCO). Individual pulmonary function parameters were
secondary exposures. The primary outcomes were 5-year NRM and the development of cGVHD. Most pa-
tients had normal lung function following transplant. A higher lung function score, signifying greater impair-
ment, was associated with an increased risk of mortality (category 1 hazard ratio [HR] 1.47 [1.17-1.85];
category 2 HR 3.38 [2.53-4.53]; category 3 HR 7.80 [4.15-14.68]). A similar association was observed for
all individual pulmonary function parameters. Low FEV1 was associated with the subsequent development
of cGVHD (FEV1 70%-79% HR 1.26 [1.01-1.57]; 60%-69% HR 1.48 [1.10-2.01]; \60% HR 2.02 [1.34-
3.05]). Models using either lung function score or individual pulmonary function parameters performed
about equally well as judged by the C-statistic. Impaired lung function at day 80 posttransplant was associated
with a higher risk of NRM. A low FEV1 following transplant was associated with developing cGVHD within
1 year.
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Pulmonary complications have been observed in
40% to 60% of patients after allogeneic hematopoietic
cell transplant (HCT). Complications may be infec-
tious or noninfectious, such as pulmonary edema,
diffuse alveolar hemorrhage, idiopathic pneumonia
syndrome, or bronchiolitis obliterans [1]. Pulmonary
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6/j.bbmt.2009.08.016posttransplant pulmonary function, including reduc-
tions in forced expiratory volume in 1 second
(FEV1), forced vital capacity (FVC), total lung capac-
ity (TLC), or a decrease in diffusion capacity for
carbon monoxide (DLCO) [2-11]. Many factors may
affect pulmonary function after HCT, including the
underlying disease process, conditioning regimen, in-
fections, and the development of acute or chronic
graft-versus-host disease (aGVHD, cGVHD) [7-9,12].
Although previous studies have characterized the
clinical scenarios associated with decreased lung func-
tion after transplantation, most cohorts were small and
primarily descriptive. One large study published in
1995 reported a 2-fold increase in risk of nonrelapse
mortality (NRM) associated with development of re-
strictive lung defects after transplantation, but restric-
tive lung disease was not associated with developing
cGVHD [5]. Despite the limitations of these studies,
they suggest that posttransplant lung function changes
may be useful for assessing a patient’s risk for various
transplant-related outcomes, such as development of
GVHD and mortality.53
54 Biol Blood Marrow Transplant 16:53-61, 2010E. C. Walter et al.In 2005, the National Institutes of Health (NIH)
Consensus Development Project on Criteria for Clin-
ical Trials in Chronic GVHD proposed new recom-
mendations to improve the diagnosis and grading of
cGVHD. Calculation of a lung function score (LFS)
was recommended to grade the extent of lung function
compromise after a diagnosis of cGVHD had been
established [13]. However, the LFS is based upon an
algorithm developed originally for grading pretrans-
plant lung function. The relationship between lung
function, mortality, and cGVHD has not been rigor-
ously analyzed using posttransplant lung function.
To address this gap, we conducted a retrospective co-
hort study of patients who underwent HCT during
a 12-year period to examine the relationship of post-
transplant pulmonary function testing (PFT) with
5-year mortality. We further evaluated the relation-
ship between posttransplant lung function and the de-
velopment of cGVHD according to NIH criteria.MATERIALS AND METHODS
Patient Selection and Clinical Data
All patients who had HCT at the Fred Hutchin-
son Cancer Research Center (FHCRC) or Seattle
Cancer Care Alliance, between January 1992 and
December 2004, were potentially eligible. Patients
who were younger than 15 years, who died before
PFT, or who did not have PFT, were excluded
(Figure 1). All clinical data except for cGVHD status
were prospectively collected and retrospectively ana-
lyzed. cGVHD data according to NIH criteria was
collected retrospectively. The patient’s underlying
disease state was categorized as low, intermediate,
or high risk, as previously described [14,15]. Donor
match status was determined according to donor-
recipient HLA compatibility. Stem cell sources were
classified as bone marrow (BM), peripheral blood
stem cell (PBSC), or a combination of both. Condi-426 (12%) age < 15 years
689 (19%) died prior to 
day 120 without PFT





Figure 1. Formation of study sample.tioning regimens were classified as nonmyeloablative
(NMA) or myeloablative (MA). Subjects in the MA
group were subdivided as receiving either a total
body irradiation (TBI) or non-TBI-based regimen.
aGVHD was graded based on stages of organ in-
volvement using standard criteria [15,16]. Ethnicity
was self-reported. Using clinical records, all patients
were followed from transplant until death or January
4, 2008. This study was approved by the institutional
review board at the FHCRC.
Lung Function Testing
All pulmonary function testing was performed at
our Center, according to American Thoracic Society
guidelines [17], using the Sensormedics 2100 (Sensor-
medics Co., Yorba Linda, CA) from January 1992 to
August 1999, and the Sensormedics V-Max 22 with Au-
tobox 6200 from September 1999 to December 2004.
Published equations for adults were used to determine
predicted values of FEV1, FVC, TLC, and DLCO
[18]. All DLCO measurements were corrected for the
hemoglobin measurement obtained closest to the
time the diffusion capacity was measured [19]. All
PFT values, except the FEV1/FVC ratio, were ex-
pressed as a percentage of predicted values and assessed
categorically. PFT categories were defined as normal
($80%), mildly abnormal (70%-79%), moderately ab-
normal (60%-69%), or severely abnormal (\60%). Per
NIH recommendations, the lung function score (LFS)
was calculated according to the day 80 FEV1 and
DLCO, each of which was mapped to a category as fol-
lows: ($80%5 1, 70%-79%5 2, 60%-69%5 3, 50%-
59% 5 4, 40%-49% 5 5, and\40% 5 6) [13,14].
Scores for FEV1 and DLCO were then summed, and
categorized 0 to 3 as defined by NIH recommendations
(LFS score 2 5 category 0 [normal]; LFS score 3-5 5
category 1 [mildly abnormal]; LFS score 6-9 5 cate-
gory 2 [moderately abnormal]; or LFS score 10-12 5
category 3 [severely abnormal]).
cGVHDAnalysis
cGVHD data was available for a subset of the co-
hort. As part of a separate study, 2602 patients with
a history of an MA transplant, between 1992 and
2005, had undergone a retrospective chart review to
establish a diagnosis of cGVHD according to current
NIH guidelines [13]. Patients who had undergone
this cGVHD assessment and who had day 80 PFT
were eligible for the cGVHD analysis.
Statistical Methods
All analyses were performed using STATA 10.0
(StataCorp, College Station, TX). Two tailed P-values
\.05 were considered statistically significant. All data
were analyzed as categorical variables except age (con-
tinuous). Robust standard errors using a sandwich








Age, years (median [IQR]) 41 (32-50) 41 (32-48)
N % N %
<20 119 6 86 5
$20 and <40 871 40 709 43
$40 and <60 1057 49 816 49
$60 111 5 39 2
Sex
Male 1247 58 948 57
Female 911 42 702 43
Ethnicity
Caucasian 1837 85 1406 85
Hispanic 107 5 80 5
Asian 42 2 35 2
American Black 32 1 22 1
Native American 24 1 22 1
Other or unknown 116 5 84 5
Disease risk at transplant
Low 772 36 614 37
Intermediate 774 36 566 34
High 611 28 470 28
Donor HLA status
HLA-matched related 1036 49 786 48
HLA-mismatched related 146 7 115 7
Unrelated 944 44 732 44
Stem cell source
Bone Marrow 1376 64 1145 69
Peripheral blood stem cell 771 36 500 30
BM, PBSC 7 <1 5 <1
Biol Blood Marrow Transplant 16:53-61, 2010 55Lung Function and Long-Term Complications after allogeneic HCTestimator were calculated for all analyses. Models were
compared using Harrell’s C-statistic. The C-statistic is
the proportion of predicted outcomes and observed
outcomes that are concordant. The primary exposure
was LFS category and primary outcome 5-year
NRM. Secondary exposures were individual PFT
parameters. Cox proportional hazards models were
used to evaluate the association between NRM and
lung function. All multivariate analyses were adjusted
for covariates that may be associated with lung func-
tion, cGVHD, and mortality. These variables included
age, sex, disease risk, conditioning regimen, HLA
status, aGVHD, and prior cytomegalovirus (CMV) in-
fection in the donor and patient as determined by sero-
logic testing. Patients who had recurrent malignancy
before PFT were excluded from hazard models
(n561). Survival was censored at 5 years from trans-
plant or at a diagnosis of recurrent malignancy.
A secondary analysis used development of cGVHD
within 1 year of PFT as the primary outcome. LFS
category was the primary exposure. Patients who had
recurrent malignancy before PFT were excluded.
Those with a diagnosis of cGVHD prior to or within
1 week of PFT were also excluded. Survival was cen-
sored at death, the onset of recurrent malignancy, or
1 year following PFT.Cord 4 <1 0 0
Cytomegalovirus serologic status, recipient-donor
Negative-negative 735 34 591 36
Negative-positive 303 14 240 15
Positive-negative 505 23 452 27
Positive-positive 609 28 364 22
Conditioning regimens
Nonmyeloablative 189 9 2 <1
Myeloablative
TBI #12Gy 534 25 461 28
TBI >12Gy 556 26 489 30
Non-TBI based 879 41 698 42
GVHD category
Acute GVHD (grade III or IV) 400 19 317 19
Chronic GVHD 846 51 846 51
Relapse status post transplant
Nonrelapsed 1550 72 1144 69
Relapsed 608 28 506 31
HLA indicates human leukocyte antigen; BM, bone marrow; PBSC, pe-
ripheral blood stem cell; Gy, gray; and GVHD, graft-versus-host disease;
TBI, total body irradiation; IQR, interquartile range.
Data were missing for the following (n): Disease risk (1), HLA status
(32), patient CMV status (1), donor CMV status (5), and acute GVHD
status (4). Numbers may not add up to 100 because of rounding.RESULTS
Between January 1992 and December 2004, 3548
patients underwent HCT. After excluding subjects
\15 years of age (12%), those who died before day
80 PFT (19%), and those without day 80 PFT data
(8%), 2158 patients were included in the analysis (Fig-
ure 1). Patients were followed for a median (interquar-
tile range [IQR]) of 1312 (251-1826) days. The median
(IQR) time from transplant until the day 80 PFT was
78 (76-83) days.
Table 1 summarizes the clinical characteristics of
the full cohort and the cohort who underwent an
analysis for GVHD. The majority of patients had nor-
mal lung function (Table 2). The mean FEV1, FVC,
and TLC were 88% 6 15%, 93% 6 16%, and 97%
6 15%, respectively. The mean DLCO was 81% 6
18% and was l\80% in 49% of patients. Twelve per-
cent of patients met criteria for obstructive lung dis-
ease, defined by a FEV1/FVC ratio\0.7. Of patients
with obstructive lung disease, the FEV1 was $80%
in nearly one-half of patients and\60% in 12% of pa-
tients. Twelve percent of patients had restrictive lung
disease, defined as TLC\80% predicted. Of patients
with restrictive lung disease, the FEV1 was $80% in
16% and\60% in 21% of patients. Forty-two percent
of patients were in LFS category 0 (Table 2). These
patients had both an FEV1 and DLCO $80% pre-
dicted. Forty-two percent of patients were in LFS cat-egory 1. These patients had either a mildly abnormal
FEV1, DLCO, or both. Nine percent of patients
were in LFS category 2, and 1% were in category 3.
Patients in LFS category 3 had severely abnormal
lung function representing both an FEV1 and
DLCO no higher than 60% predicted. Five-year all-
cause mortality was 40% and 5-year NRM was 20%.
Five-year relapse was 28%.
Seventy-two patients (4%) were diagnosed with
cGVHD before or within 1 week of PFT, and were
Table 2. Distribution of Day 80 Pulmonary Function Test (PFT) Parameters, Lung Function Score, and Lung Function Score
Categories
Lung function parameters; N (%)
PFT parameter $80% 70% - 79% 60% - 69% < 60% Mean (% predicted) SD)
FEV1 1566 (73) 347 (16) 155 (7) 90 (4) 88 (15)
FVC 1732 (80) 259 (12) 112 (5) 55 (3) 93 (16)
TLC* 1779 (88) 174 (9) 49 (2) 17 (<1) 97 (15)
DLCO† 1035 (51) 424 (21) 329 (16) 224 (11) 81 (18)
FEV1/FVC $ 0.7 < 0.7
1908 (88) 250 (12) 0.78 (0.07)
Lung Function Scores and Lung Function Score Categories
LFS Frequency† N (%) LFS Category Frequency N (%)
2 896 (42) 0 896 (42)
3 427 (20)




8 30 (1) 2 198 (9)
9 16 (1)
10-12 20 (1) 3 20 (1)
FEV1 indicated forced expiratory volume in 1 second; DLCO, carbon monoxide diffusion capacity; FVC, forced expiratory vital capacity; TLC, total lung
capacity.
LFS categories were calculated as follows: Category 0 5 LFS 2, category 1 5 LFS 3-5, category 2 5 LFS 6-9, category 3 5 LFS 10-12.
*TLC only available for 2019 (94%) patients.
†DLCO and LFS only available for 2012 (93%) patients.
56 Biol Blood Marrow Transplant 16:53-61, 2010E. C. Walter et al.excluded from the cGVHD analysis. The remaining
1650 patients evaluated for cGVHD were similar to
the entire cohort except a slightly higher percentage
had a BM stem cell source (69%), and very few
(\1%) had an NMA conditioning regimen (Table 1).
The distribution of day 80 PFTs for this cohort is sum-
marized in Table 3. Overall, 846 (51%) developedTable 3. Distribution of Day 80 Posttransplant Pulmonary Funct
Function Score Categories Among Patients Included in the GVHDA
Lung Function Param
PFT parameter $80% 70% - 79%
FEV1 1214 (74) 255 (14)
FVC 1340 (81) 186 (11)
TLC* 1360 (82) 135 (8)
DLCO† 789 (48) 337 (20)
FEV1/FVC $0.7 < 0.7
1461 (89) 189 (11)
Lung Function Scores and Lung F










FEV1 indicates forced expiratory volume in 1 second; DLCO, carbon monoxide
capacity; GVHD, graft-versus-host disease.
LFS categories were calculated as follows: Category 0 5 LFS 2, category 1 5
*TLC only available for 1542 (93%) patients.
†DLCO and LFS only available for 1538 (93%) patients.cGVHD and 726 were diagnosed within 1 year of
PFT.
Lung Function and Mortality
Diminished lung function at day 80 posttransplant
was associated with an increased risk of NRM at 5 years
as measured by lung function score (Table 4). Patientsion Test Parameters, Lung Function Scores (LFS), and Lung
nalysis
eters; N (%)
60% - 69% < 60% Mean (% predicted) (SD)
122 (7) 59 (4) 88(15)
86 (5) 38 (2) 94 (16)
37 (2) 10 (1) 97 (14)
258 (16) 154 (9) 81 (18)
0.78 (0.07)
unction Score Categories





diffusion capacity; FVC, forced expiratory vital capacity; TLC, total lung
LFS 3-5, category 2 5 LFS 6-9, category 3 5 LFS 10-12.
Table 4. Risk of Five-Year Nonrelapse Mortality as a Function of Pulmonary Function Parameters (PFT)
PFT parameter N Unadjusted HR (95% CI) P-value Adjusted HR‡ (95% CI) P-value
LFS category 1855
0 816 Referent Referent
1 839 1.47 (1.17-1.85) .001 1.37 (1.08-1.75) .011
2 182 3.38 (2.53-4.53) <.0005 3.02 (2.11-4.33) < .0005
3 18 7.80 (4.15-14.68) <.0005 8.56 (4.54-16.14) < .0005
Trend <.0005 Trend <.0005
FEV1 1999
$80% 1451 Referent Referent
70% - 79% 327 1.76 (1.38-2.24) <.0005 1.56 (1.19-2.06) .002
60% - 69% 139 2.33 (1.68-3.25) <.0005 2.57 (1.75-3.76) < .0005
<60% 82 5.79 (4.28-7.85) <.0005 4.88 (3.19-7.47) < .0005
Trend <.0005 Trend <.0005
FVC 1999
$80% 1612 Referent Referent
70% - 79% 339 2.37 (1.84-3.04) <.0005 2.26 (1.72-2.97) < .0005
60% - 69% 100 2.74 (1.96-3.85) <.0005 2.76 (1.84-4.15) < .0005
<60% 48 6.65 (4.54-9.76) <.0005 7.79 (5.00-12.14) < .0005
Trend <.0005 Trend <.0005
TLC 1870
$80% 1650 Referent Referent
70% - 79% 159 2.42 (1.80-3.24) <.0005 2.18 (1.56-3.04) <.0005
60% - 69% 46 4.28 (2.79-6.56) <.0005 4.03 (2.65-6.12) <.0005
<60% 15 2.47 (1.02-6.02) .046 3.42 (1.42-8.23) .006
Trend <.0005 Trend <.0005
DLCO 1856
$80% 945 Referent Referent
70% - 79% 397 0.99 (0.74-1.33) .966 1.05 (0.78-1.42) .745
60% - 69% 305 2.04 (1.57-2.66) <.0005 1.88 (1.38-2.57) < .0005
<60% 209 2.59 (1.96-3.43) <.0005 2.58 (1.86-3.57) < .0005
Trend <.0005 Trend <.0005
FEV1 indicates forced expiratory volume in 1 second; DLCO, carbon monoxide diffusion capacity; FVC, forced expiratory vital capacity; TLC, total lung
capacity; CI, confidence interval; HR, hazard ratio.
‡Adjusted for age, sex, disease risk, conditioning regimen, HLA status, acute GVHD grade, cytomegalovirus (CMV) status of donor and patient and pre-
HCT lung function. Results do not include patients who had recurrent malignancy before pulmonary function was evaluated.
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death. This risk increased to more than 3-fold for pa-
tients in category 2 and nearly 8-fold in category 3.
All hazard ratio estimates were statistically significant.
The trend of increased mortality with increasing LFS
category was statistically significant (P\ .0005). After
adjustment for age, sex, disease risk, conditioning reg-
imen, HLA compatibility, aGVHD, donor and patient
CMV status, and pre-HCT lung function, hazard ra-
tios were largely unchanged (category 1 HR 1.37
[1.08-1.75]; category 2 HR 3.02 [2.11-4.33]; category
3 HR 8.56 [4.54-16.14]). The trend remained statisti-
cally significant (P\ .0005).
There was also a stepwise increase in risk of mortal-
ity associated with individual PFT parameters (Table
4). Compared to a normal FEV1, a mildly decreased
FEV1 was associated with a 76% increased risk of mor-
tality (HR 1.76 [1.38-2.24]). The HR increased to 2.33
(1.68-3.25) and 5.79 (4.28-7.85), for a moderately and
severely decreased FEV1, respectively. A similar in-
crease in HR was seen for FVC. Although the relation-
ship was not as distinct for TLC categories, hazard
ratio estimates for each category were also significantly
increased. For DLCO, this association was only signif-
icant for categories 2 and 3 (category 2 HR 2.04 [1.57-
2.66]; category 3 HR [1.96-3.43]). Similar to LFS, thetrend toward increased mortality with decreasing
pulmonary function was statistically significant for all
PFT parameters (P\ .0005). Figure 2 demonstrates
5-year cumulative incidence of NRM as a function of
PFT parameters and LFS categories. After adjustment,
hazard ratio estimates were largely unchanged and re-
mained statistically significant for all PFT parameters
except DLCO category 1. There was no significant re-
lationship between mortality and FEV1/FVC ratio
(HR 1.11 [0.92-1.36]).Lung Function and cGVHD
A moderately or severely decreased LFS category
was associated with a significantly increased risk of de-
veloping cGVHD within 1 year of PFT (Category 2
HR 1.38 [1.02-1.86]; and Category 3 HR 2.93 [1.00-
8.55]) (Table 5). The trend for an increased risk of
developing cGVHD as LFS increased was also signif-
icant (P5.037). This was primarily because of a strong
association between FEV1 and cGVHD, as DLCO
was not associated with cGVHD in any category. A
mildly abnormal FEV1 was associated with a 26% in-
creased risk of cGVHD. This risk increased to 48%
for a moderately abnormal FEV1 and was more than
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Figure 2. Cumulative incidence of NRM as a function of day 80 PFT parameters and LFS categories.
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ditioning regimen, aGVHD status, and pre-HCT lung
function, hazard ratios were largely unchanged. The
trend of an increased hazard ratio with decreasing
FEV1 was significant in both adjusted and unadjusted
analyses (P\ .0005). Similar to FEV1, there was a sig-
nificant trend of an increased risk of cGVHD with de-
creasing FVC (P5.001). Within categories of FVC
this association was only significant when FVC was
\60% predicted (HR 2.39 [95% confidence interval
[CI] 1.48-3.86]). TLC was not associated with an in-
creased risk of developing cGVHD.To evaluate the performance of the LFS and indi-
vidual PFT parameters as potential predictors of
5-year NRM and cGVHD, we compared the Harrell’s
C-statistic for each of the above times to event multivar-
iate models. Overall, models using either the LFS or in-
dividual PFT parameters performed similarly. With
respect to adjusted 5-year mortality, the C-statistic
was 0.74 for the LFS, FEV1, and FVC models, and
0.73 for TLC and DLCO models. C-statistics were
also similar between adjusted cGVHD models
(C-statistic50.60 for LFS and FEV1; C-statistic50.59
for FVC, TLC, DLCO).
Table 5. Risk of Developing Chronic GVHD within 1 Year as a Function of Pulmonary Function Parameters
PFT Parameter N Unadjusted HR (95% CI) P-Value Adjusted HR* (95% CI) P-Value
LFS category 1373
0 619 Referent Referent
1 621 1.04 (0.88-1.24) .623 1.01 (0.84-1.22) .902
2 123 1.38 (1.02-1.86) .035 1.40 (1.00-1.95) .048
3 10 2.93 (1.00-8.55) .049 3.11 (1.09-8.89) .035
Trend5.037 Trend5.072
FEV1 1477
$80% 1090 Referent Referent
70% - 79% 227 1.26 (1.01-1.57) .038 1.23 (0.97-1.56) .086
60% - 69% 106 1.48 (1.10-2.01) .010 1.50 (1.06-2.13) .023
<60% 54 2.02 (1.34-3.05) .001 2.23 (1.43-3.47) <.0005
Trend <.0005 Trend <.0005
FVC 1477
$80% 1205 Referent Referent
70% - 79% 168 1.21 (0.94-1.56) .135 1.19 (0.91-1.56) .212
60% - 69% 71 1.27 (0.86-1.88) .230 1.29 (0.83-2.00) .253
<60% 33 2.39 (1.48-3.86) <.0005 2.49 (1.46-4.24) .001
Trend5.001 Trend5.002
TLC 1381
$80% 1220 Referent Referent
70% - 79% 117 0.92 (0.66-1.29) .631 0.97 (0.69-1.37) .880
60% - 69% 34 1.31 (0.74-2.32) .357 1.58 (0.88-2.82) .124
<60% 9 0.87 (0.26-2.88) .824 1.22 (0.31-4.76) .772
Trend5.851 Trend5.343
DLCO 1375
$80% 704 Referent Referent
70% - 79% 307 0.96 (0.78-1.17) .661 0.97 (0.78-1.19) .751
60% - 69% 228 0.96 (0.75-1.23) .767 0.96 (0.73-1.25) .746
<60% 135 1.23 (0.93-1.62) .156 1.22 (0.90-1.66) .206
Trend5.431 Trend5.499
FEV1 indicates forced expiratory volume in 1 second; DLCO, carbon monoxide diffusion capacity; FVC, forced expiratory vital capacity; TLC, total lung
capacity; CI, confidence interval; HR, hazard ratio.
*Adjusted for age, sex, disease risk, condition regimen, diagnosis of acute GVHD and pre-HCT lung function. Results do not include patients who had
recurrent malignancy before pulmonary function was evaluated or patients were diagnosed with chronic GVHD before or within 1 week of pulmonary
function testing.
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Although previous studies have evaluated lung
function after HCT [2-11], few studies have critically
examined whether lung function observed within the
first 100 days after transplantation is associated with
long-term clinical events. Instead, several previous
studies have suggested that pulmonary function abnor-
malities within the first 6 months after transplant may
be the result of peritransplant events, may be reversible,
and may have no prognostic value [2]. Our results show
the contrary, indicating that diminished lung function
at day 80 following transplant was significantly associ-
ated with poor long-term outcomes. Most importantly,
patients with the most severely abnormal lung func-
tion, as measured by the LFS, had a nearly 8-fold higher
risk of 5-year NRM. An increased risk was also seen
with individual pulmonary function parameters. Our
results also show that early posttransplant pulmonary
dysfunction may identify patients at risk of developing
cGVHD. Although this relationship was present for
the LFS, the clearest association was with FEV1. These
results suggest that diminished lung function post-
transplant should not be dismissed as a transient find-
ing. Moreover, routine pulmonary function testing
following transplant may identify a group of higherrisk patients who need to be followed closely for post-
transplant complications and signs of cGVHD.
Models using either the LFS or individual PFT pa-
rameters performed similarly. These results suggest
that individual PFT parameters, especially FEV1,
may be as informative as the LFS, making it reasonable
to assess spirometry alone for routine monitoring of
lung function after HCT. This practice would result
in a decrease in cost and increase in accessibility of
lung function monitoring, and thus increase the likeli-
hood that monitoring will be adopted more widely as
standard clinical practice for the management of all
HCT patients.
Crawford et al. [5] previously showed that dimin-
ished lung function after transplant was associated
with late mortality. A restrictive lung defect at day 80
or a decrease in TLC of 15% or greater from baseline
was associated with a 2-fold increased risk of mortality.
FEV1/FVC ratio and DLCO were not significantly as-
sociated with mortality. In our study, all PFT parame-
ters except for FEV1/FVC ratio were associated with
mortality. Several reasons might explain why our re-
sults differ. Crawford et al. [5] classified an abnormal
DLCO as\80%, a threshold that may have been too
high to identify patients with clinically significant pul-
monary compromise. Our study was larger, and divided
60 Biol Blood Marrow Transplant 16:53-61, 2010E. C. Walter et al.patients with an abnormal DLCO into groups of mild,
moderate, and severe. We did not find a significant as-
sociation for patients with a mildly abnormal DLCO
(70%-80%), but an association was present for
a DLCO \70%. Furthermore, Crawford et al. [5]
described a cohort who had HCT before 1990. Post-
transplant care has changed significantly since then.
Nonmyeloablative conditioning regimens are now
frequently used and associated with fewer pulmonary
complications [20], and preemptive antifungal and
anti-CMV treatment are also more readily available
[21]. Both changes have improved outcomes after
HCT.
Crawford et al. [5] did not detect an association
between TLC and cGVHD. We also did not find an
association between TLC and cGVHD. cGVHD of
the lungs manifests as bronchiolitis obliterans and air-
flow obstruction, which may explain why FEV1, and
not TLC, was associated with the development of
cGVHD in our study.
Pulmonary dysfunction following HCT has sev-
eral possible causes. Patients are at increased risk of
respiratory infections due to prolonged immunosup-
pression [1,21]. Chemotherapeutics may have direct
toxic effects such as damage to vascular endothelium
or alveoli resulting in a decreased DLCO. Chest
wall, mediastinal, or TBI may have short- and long-
term effects on pulmonary function [22]. aGVHD
and cGVHD have been previously associated with di-
minished posttransplant pulmonary function [4,7,9].
However, previous studies were unable to ascertain
whether diminished pulmonary function was the result
of cGVHD or was an early marker of cGVHD. Addi-
tionally, these studies were conducted before NIH
consensus definitions. Strengths of our study were
ascertainment of the date cGVHD was diagnosed, re-
striction of our analysis to patients without a diagnosis
of cGVHD at day 80, and the use of current NIH
criteria for the diagnosis of cGVHD.
Our results should be interpreted with some cau-
tion. First, day 80 PFTs were not available for the
entire cohort. A post hoc analysis of patients who sur-
vived to at least 60 days, and therefore could have had
PFT but did not (n5527, 15%), showed that 81% of
these patients died. It may be that patients missing
PFT carried a higher burden of illness and were either
unable to have testing, or providers were reluctant to
subject them to testing. If true, this practice would
tend to bias our results away from the null hypothesis
and strengthen our findings. Second, our single center
results might not apply to other centers. In the GVHD
analysis, we used current NIH diagnostic criteria in an
attempt to minimize this limitation. Third, the diagno-
sis of cGVHD according to NIH criteria was retro-
spective and subject to misclassification; and some
patients may have had undiagnosed cGVHD when pul-
monary function was evaluated. Finally, we were un-able to determine the cause of NRM, as patients are
routinely discharged from our Center around day
100. Many deaths then occur outside the Seattle region.
In summary, we have shown that decreased pulmo-
nary function after transplant was associated with an in-
creased risk of 5-year NRM. Decreased FEV1 was also
associated with the development of cGVHD within the
first year after the day 80 PFT. Pulmonary dysfunction
can be graded with the NIH recommended LFS, but
a simple assessment of FEV1 can provide similarly use-
ful clinical information. Future studies should focus on
validation of our findings, and should examine these as-
sociations using additional pulmonary function assess-
ments at 1 year or later following transplant. In the
meantime, these data provide evidence supporting the
NIH recommendation that pulmonary function should
be routinely monitored after HCT. Patients who have
significantly abnormal lung function should be fol-
lowed closely for complications or signs of cGVHD.ACKNOWLEDGMENTS
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